CTRI/2017/09/009851已完成4 期
Recurrence of dermatophytosis and therapeutic efficacy of systemic antifungals in adults â?? A randomized, open-label controlled trial in a tertiary institution.
Chinmay Kar0 个研究点目标入组 155 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 155
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(1) Adult patients (15-60 years) with recurrent tinea corporis, cruris or faciei or combinations of these attending our Dermatology OPD, will be the candidates of this study. Most of them present with an extensive form.
- •(2) They have a history of Cap Itraconazole intake (100mg twice daily for at least one month) without interruption and re-occurrence of similar form of tinea after stopping Itraconazole within a short period (one week to six weeks).
- •(3) They must have normal blood count, liver and renal function tests.
- •(4) Positive KOH smear on skin scraping.
- •(5) Regular follow up is possible and complied with to note the improvement and/or any other complications.
排除标准
- •(1)Patients with Diabetes Mellitus or other immunocompromised disorders.
- •(2)Patients with H/O steroid or immunosuppressant medicines intake.
- •(3) Pregnant or lactating mother.
- •(4) Other family members will have chronic tinea infections.
- •(5) Patients with other form of tinea infection like tinea pedis, tinea manuum, tinea unguium etc.
研究者
相似试验
尚未招募
Unknown
Validation Of Dermatphytosis Severity Score And Its Correlation With Patient ReportedOutcome MeasuresCTRI/2023/07/054989Father muller research centre
已完成
不适用
understanding the epidemiology and various parameters of practice followed by dermatologists for recalcitrant dermatophytosis.CTRI/2021/04/033227GCSMCHRC Ahmedabad
尚未招募
Unknown
Co-relation of severity of ringworm with blood ferritin level-An observational studyCTRI/2023/08/056637DrSarithaM
已完成
不适用
Clinical Profile of Ringworm in patients attending Homoeopathy OPDCTRI/2022/01/039559All India Institute of Medical Sciences103
已完成
不适用
Observational study of treatment of epidermal growth factor receptor activating mutation positive(EGFRm+)advanced or recurrent non-small-cell lung cancerAdvanced lung cancerJPRN-UMIN000010538C-02 Executive committee500
